Tilatamig samrotecan
AstraZeneca's EGFR×c-MET bispecific ADC, the most advanced in the most crowded next-generation ADC target pair.
Designed with a low-affinity EGFR arm and high-affinity c-MET arm to bias delivery toward tumour cells co-expressing both. In phase 2 in EGFR-mutant NSCLC after osimertinib and in EGFR-wild-type NSCLC, per AstraZeneca's 2026 pipeline. Among ~24 c-MET×EGFR ADC candidates.
Tilatamig samrotecan carries a camptothecin-derived TOP1 inhibitor; exatecan shown as the class representative.
1.Antibody binds EGFR and c-MET (bispecific) on the tumour cell surface
- Route
- IV infusion
- Schedule
- Phase 2 dose-optimisation; every 3 weeks
Source: clinicaltrials.gov/study/NCT05647122. Doses are for orientation; the current label governs.
| Adverse event |
|---|
| Stomatitis |
| Nausea |
| Fatigue |
| Neutropenia |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Tilatamig samrotecan" OR ABSTRACT:"Tilatamig samrotecan" OR TITLE:"AZD9592" OR ABSTRACT:"AZD9592") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tilatamig samrotecan, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductAK146D1
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, Bispecific ADC, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs.
- ProductPuxitatug samrotecan
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, AstraZeneca.
- ProductIzalontamab brengitecan
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, Bispecific ADC, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares MET, EGFR, Non-small-cell lung cancer.
- TrialTeliMET NSCLC-01
Shares MET, Non-small-cell lung cancer.
- PersonDae Ho Lee
Shares MET, EGFR, Non-small-cell lung cancer.
- PersonJohn V. Heymach
Shares EGFR, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- ProductGefitinib
Shares AstraZeneca, EGFR, Non-small-cell lung cancer.